Combination Shows Promise in Metastatic ESR1-Mutant Breast C

Durable responses with lasofoxifene plus abemaciclib in post-CDK4/6 inhibitor setting

Related Keywords

Massachusetts , United States , Boston , Texas , Minnesota , Mayo Clinic In Rochester , Houston , Matthew Goetz , Dsenthil Damodaran , Charles Bankhead , University Of Texas Md Anderson Cancer Center , Harvard Medical School , Cancer Center , Mayo Clinic , Seth Wander , Massachusetts General Hospital , Medpage Today ,